03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Vapreza 100 : | |
Type | Medicine Authorised |
Originator | Vidaza |
Agent | Pharmamed |
Distributor | Pharmamed |
Laboratory | Natco Pharma |
Manufacturer | Pharmaline SAL* |
Manufacturing Type | Pharmaline SAL Licensed by Natco Pharma Ltd, India |
Origin | Lebanon |
ATC | L01BC07 |
Vapreza 100 :
Vapreza 100 :
Vapreza 100 :
Vapreza 100 :
Vapreza 100 :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Very Common |
Acute febrile neutrophilic dermatosis (Sweet's syndrome) | Uncommon |
Alopecia | Common |
Anaemia | Very Common |
Anaphylactoid reactions | Not known |
Anorexia | Very Common |
Anxiety | Common |
Arthralgia (Pain joint) (Joint ache) | Very Common |
Bleeding | Not known |
Bone marrow failure | Common |
Cardiac disorder | Not known |
Cellulitis | Common |
Cerebral haemorrhage | Not known |
Chest pain | Very Common |
Coma hepatic | Uncommon |
Confusional state | Common |
Conjunctival haemorrhage | Common |
Constipation | Very Common |
Diarrhoea (Diarrhea) | Very Common |
Dizziness | Very Common |
Dyspepsia | Common |
Dyspnoea (dyspnea) | Very Common |
Dyspnoea exertional | Common |
Ecchymosis | Very Common |
Erythema | Common |
Eye haemorrhage | Common |
Fatigue | Very Common |
Febrile neutropenia (Neutropenic fever) | Very Common |
Gastroduodenal haemorrhage | Common |
Gingival bleeding (Gingival hemorrhage) | Common |
Haematoma | Common |
Haematuria (Hematuria) | Common |
Haemorrhage intracranial | Common |
Haemorrhoidal haemorrhage | Common |
Headache | Very Common |
Hepatic failure (Hepatic insufficiency) (Liver failure) | Uncommon |
Herpes simplex | Common |
Hypersensitivity reactions | Uncommon |
Hypertension | Common |
Hypokalaemia | Common |
Hypotension | Common |
Injection site bruising | Common |
Injection site discolouration | Common |
Injection site erythema | Very Common |
Injection site haematoma | Common |
Injection site haemorrhage | Common |
Injection site induration | Common |
Injection site inflammation | Common |
Injection site necrosis | Rare |
Injection site nodule | Common |
Injection site pain | Very Common |
Injection site pruritus | Common |
Injection site rash | Common |
Injection site reaction | Very Common |
Insomnia | Common |
Interstitial pneumonitis | Rare |
Lethargy | Common |
Leucopenia (Leukopenia) | Very Common |
Malaise | Common |
Musculoskeletal pain | Common |
Myalgia | Common |
Nasopharyngitis | Very Common |
Nausea | Very Common |
Necrotizing fasciitis | Not known |
Neutropenia | Very Common |
Neutropenic sepsis | Common |
Pancytopenia | Common |
Petechiae | Very Common |
Pharyngitis | Common |
Pharyngolaryngeal pain | Common |
Pneumonia | Very Common |
Pruritus | Very Common |
Purpura | Common |
Pyrexia | Very Common |
Rash macular | Common |
Renal failure | Common |
Renal tubular acidosis | Uncommon |
Rhinitis | Common |
Serum creatinine increased | Common |
Sinusitis | Common |
Skin lesion | Not known |
Skin rash | Very Common |
Stomatitis | Common |
Thrombocytopenia (Thrombopenia) | Very Common |
Tumour lysis syndrome | Rare |
Upper respiratory tract infection | Common |
Urinary tract infection | Common |
Vomiting | Very Common |
Weight decreased (Weight loss) | Common |
Vapreza 100 :
NB : Products With Same Indication |
Different Units By MoH Code
Vapreza 100 MoH 10683 :
Form | Powder for suspension for injection |
Package Size | 1x4ml |
Strength | 100mg |
Public Price | 22812649.27 L.L. |
Stratum | D |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 3919/1 |
Submission date | 14/01/2019 |
Registration Year | 24/06/2021 |
Pending Year | 10/10/2019 |
Pending Reason | Incomplete file |
Price Comparison
● Country: | Lebanon | |
● Form: | Powder for suspension for injection | |
● Package Size: | 1x4ml | |
● Public Price: | 22812649.27 LBP | ( 22,812,649.27 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 22812649,27 LBP | ( 22,812,649.00 LBP ) |
● Pricing Date: | 13/06/2024 |
You have to register to view this info
Drop File